U.S., Nov. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07226531) titled 'Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US' on Sept. 22.
Brief Summary: Alopecia areata (AA) is a chronic, relapsing T-cell mediated autoimmune disease characterized by nonscarring, typically patchy hair loss that affects people of all ages, races, and genders. In the United States (US), AA has an estimated point prevalence of 1.14% (Beningo et al., 2020). The three most common subtypes of AA are defined by the affected area:
* Patchy alopecia (PA), as seen in 90% of clinical diagnoses: hair loss occurring in one or more patches (ranging from coin-sized to large patches and eve...